A Study of the Long-term Safety and Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial Dilated Cardiomyopathy
← catalyst calendarNCT07771465 · readout ≤ 2,295 d
Sponsored by Kardigan, Inc. (industry) · KARD — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
332estimated
Sites
78
Countries
Belgium, Denmark, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Genetic Dilated Cardiomyopathy (DCM)
Intervention
- Drug: Danicamtiv
Primary outcomes
what the primary-completion date above is the date OFFrequency and severity of treatment-emergent adverse events (TEAEs)
measured 61 months
Frequency and severity of adverse events of special interest (AESIs)
measured 61 months
Frequency and severity of serious adverse events (SAEs)
measured 61 months
Frequency and severity of disease-related events (DREs)
measured 61 months
Frequency of abnormal findings from physical examination
measured 61 months
Frequency of abnormal findings from vital signs
measured 61 months
Frequency of abnormal findings from 12-lead electrocardiograms (ECGs)
measured 61 months
Frequency of abnormal findings from clinical laboratory assessments
measured 61 months
Permalink · KARD's whole pipeline · Catalyst calendar · Every registered study · What changed